不同生长激素预处理时间对卵巢储备功能减退患者辅助生殖治疗效果的影响：一项回顾性前瞻性队列研究。
Effect of different growth hormone pretreatment times in assisted reproductive therapy for patients with diminished ovarian reserve: A retrospective pilot cohort study.
机构信息
Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology.
出版信息
Medicine (Baltimore). 2024 Sep 13;103(37):e39645. doi: 10.1097/MD.0000000000039645.
This study aimed to evaluate the effect of different growth hormone (GH) pretreatment times in assisted reproductive therapy in patients with diminished ovarian reserve (DOR). A retrospective pilot cohort analysis was performed on patients with DOR receiving GH pretreatment in the Assisted Reproduction Unit of Sir Run Run Shaw Hospital. A total of 1459 patients met the criteria and were divided into four groups according to GH pretreatment time as follows: 53 were in the 2-month pretreatment group (GH1), 400 were in the 1-month pretreatment group (GH2), 414 were in the ovulation induction period pretreatment group (GH3), and 592 were in the non-GH pretreatment group (control group). In addition, GH1, GH2, and GH3 were combined in the GH pretreatment group. Baseline characteristics and treatment outcomes were compared between the groups. The number of oocytes retrieved in the GH pretreatment, GH1, GH2, and GH3 groups was significantly higher than that in the control group (all P < .01). The numbers of oocytes retrieved in the GH1 and GH2 groups were similar but were nominally higher than those in the GH3 group. Estradiol concentrations in the GH pretreatment, GH2, and GH3 groups were significantly higher than those in the control group on the day of human chorionic gonadotropin injection (all P < .01). In the GH1 group, 22 patients had >1 assisted reproductive therapy cycle (non-GH pretreatment) before GH pretreatment, and the number of oocytes retrieved in the GH pretreatment cycle was higher than that in the non-GH pretreatment cycle, but this was not significant. These findings suggest that the GH pretreatment time was appropriately prolonged, and the number of oocytes retrieved nominally increased. In patients with DOR, GH pretreatment improved treatment outcomes. More than 1 month of GH pretreatment did not increase the number of oocytes retrieved.
本研究旨在评估不同生长激素（GH）预处理时间对卵巢储备功能减退（DOR）患者辅助生殖治疗的影响。我们对在浙江大学医学院附属邵逸夫医院生殖医学中心接受 GH 预处理的 DOR 患者进行了回顾性前瞻性队列分析。共有 1459 名符合标准的患者，根据 GH 预处理时间分为四组：53 例为 2 个月预处理组（GH1），400 例为 1 个月预处理组（GH2），414 例为诱导排卵期预处理组（GH3），592 例为非 GH 预处理组（对照组）。此外，GH1、GH2 和 GH3 合并为 GH 预处理组。比较各组的基线特征和治疗结局。GH 预处理组、GH1 组、GH2 组和 GH3 组的获卵数明显高于对照组（均 P<0.01）。GH1 组和 GH2 组的获卵数相似，但略高于 GH3 组。GH 预处理组、GH2 组和 GH3 组在人绒毛膜促性腺激素注射日的雌二醇浓度明显高于对照组（均 P<0.01）。在 GH1 组中，22 例患者在 GH 预处理前有>1 个辅助生殖周期（非 GH 预处理），GH 预处理周期的获卵数高于非 GH 预处理周期，但差异无统计学意义。这些发现表明，GH 预处理时间适当延长，获卵数略有增加。在 DOR 患者中，GH 预处理可改善治疗结局。超过 1 个月的 GH 预处理不会增加获卵数。
Zotero 插件